UNSPSC 51402204: Duloxetine

This classification denotes an antidepressant agent with the molecular formula C18H19NOS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O5TNM5N07U, chemically known as 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1h-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-2h-benzimidazol-2-one but generally known as duloxetine, which bears US NIH Compound Identifier 3151. European Medicines Agency schedules Duloxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06424MIG.

UNSPSC 51402204 Duloxetine is a Commodity code nominally covering a specific antidepressant pharmaceutical, but recent state and local procurement activity under this code shows a significant mismatch — the only recent solicitation tracked involves naloxone and drug deactivation systems, which fall outside the therapeutic scope of duloxetine. State and local governments do not appear to be issuing public solicitations for duloxetine acquisition through this code channel at present.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The contract carries a two-year initial term with a one-year renewal option, includes a three-month probationary termination clause, and is potentially funded through FEMA, triggering Clean Air Act and Federal Water Pollution Control Act compliance. Vendors must meet standard requirements including drug-free workplace certification, E-Verify compliance, and specified insurance coverages. The mismatch between the code's nominal pharmaceutical scope and actual procurement activity suggests either a data-entry error in the opportunity's UNSPSC tagging or that this code sees minimal relevant state and local solicitation volume.